Why women aged 50-plus are still under-researched—clinically, nutritionally, and now algorithmically
The Women’s Health Research Gap: Tea, Trials, and the Trouble with “Male as Default”

Introduction

This white paper began, as many questionable decisions do, with curiosity and the firm belief that “surely someone has already put all of this together”. “This” meaning a gender gap in research – especially when it comes to women aged 50 and 60-plus, or Generation Jones. I often feel we are excluded when I analyse the latest studies. And I was right: the research community had not looked into this in the way I expected – or at least not in one place, with the data, the sources, and the inconvenient details that tend to get quietly skipped.

Over time, while writing blog articles on the subject, a pattern emerged: important parts were missing. Not the sort you can ignore with a polite cough, but rather large gaps – the kind you could lose a small car in. Given that the topic wanders across several areas of expertise, this is perhaps understandable. Still, to me, it was mildly irritating.

The result is this document. It contains the numbers, the references, and the original sources. It also contains very little in the way of narrative excitement. This is not a page-turner. No one will stay up late reading it with a cup of tea, whispering, “Just one more section.” It is, unapologetically, thorough.

Think of this white paper as the sensible friend: dependable, accurate, slightly dull at dinner parties, but exactly who you want when facts matter. It exists so you can check claims, follow the trail back to the source, and avoid saying something confident and wrong in public.

Because not everyone wishes to spend their leisure time reading footnotes, the material has been broken down into a series of shorter articles. These are the chatty ones. Each focuses on a specific topic and aims to leave you thinking, “Right then. I understand this now, and I know what to do next.”

As those articles are published over the coming weeks, they will be linked here in the introduction. Start there if you like. Come back here when you want the evidence. And if, at any point, this document feels a bit serious, just imagine two British ladies exchanging looks over their teacups and agreeing that, yes, it’s terribly dry – but rather useful.

OK, so what is this about?

The human longevity landscape presents a persistent biological and sociological enigma: while women consistently outlive men, they spend a significantly higher proportion of their lives in poor health, a phenomenon often described as the male–female health-survival paradox. [1, 2, 3] This discrepancy is not merely a by-product of intrinsic biological ageing but is profoundly exacerbated by a historical and systemic neglect of women aged 50 and older in scientific research. [2, 4, 5]

For decades, medical and nutritional sciences have operated under an androcentric, or “male-as-default” (yes, I had to look this one up), model, wherein the female body is treated as a physiological variant of the male standard, often framed as a complication due to hormonal fluctuations and reproductive cycles. [6, 7] As women cross the threshold of 50 – a period typically defined by the pivotal transition of menopause – they enter a “research desert” in which their specific physiological, nutritional, and technological needs are frequently ignored or misattributed. [8, 9, 10]

This report examines the multifaceted extent of this neglect across four critical domains: clinical health, nutritional science, longevity research, and the emerging field of artificial intelligence. By synthesising current data on clinical trial participation, metabolic shifts, evolutionary biology, and algorithmic bias, the analysis shows that the neglect of women over 50 is a structural failure that compromises the efficacy of modern medicine and the promise of healthy ageing. [4, 7, 11, 12]

Structural Invisibility in Clinical Research and Medical Trials

The underrepresentation of women in clinical trials is a legacy of protectionist policies that effectively institutionalized sex bias in medical research.[13, 14] Between 1977 and 1993, the United States Food and Drug Administration (FDA) implemented guidelines that excluded women of “childbearing potential” from early-phase clinical research to prevent potential fetal harm, a policy that was broadly applied and essentially excluded the majority of women from medical research for nearly two decades.[6, 13, 14] Although the NIH Revitalization Act of 1993 mandated the inclusion of women, the scientific community has struggled to rectify the resulting data gap, particularly for older women who fall outside the traditional reproductive window.[6, 13, 15]

The Age-Sex Enrolment Gradient

Recent systematic reviews and meta-analyses highlight a concerning trend: as the average age of clinical trial participants increases, the proportion of female enrolment decreases.[16]

While the median enrolment rate for women across all fields is approximately 41%, this figure is not static across age groups.[16]

Average Age of Trial Participants	Median Enrolment Rate of Women	Statistical Significance (p-value)
≤ 45 years	47% (IQR 30–64)	p < 0.001 [16]
46–55 years	46% (IQR 33–58)	p < 0.001 [16]
56–62 years	38% (IQR 27–50)	p < 0.001 [16]
≥ 63 years	33% (IQR 20–46)	p < 0.001 [16]

This gradient demonstrates that women over 50 face a “double burden” of exclusion based on both sex and age. The reduction in participation for women aged 63 and older to just 33% creates a critical knowledge deficit regarding the benefit-risk profiles of treatments in a demographic that is often the primary consumer of these medical interventions.[11, 16] This exclusion is frequently justified by researchers through eligibility criteria that prioritize “organ-system abnormalities” or “functional status limitations,” which disproportionately filter out older women who may have co-morbidities.[17] Estimates suggest that relaxing these arbitrary restrictions could increase the participation of elderly adults in cancer trials from 32% to nearly 60%.[17]

Disparities in Disease-Specific Representation

The neglect of women 50 plus is particularly acute in fields where they bear a high disease burden, such as cardiology and oncology. [5, 18, 19]

Cardiovascular disease (CVD) remains the leading cause of death for women, yet women continue to be under-represented and understudied in CVD clinical trials. [19, 20, 21]

Historically, CVD was perceived as a “man’s disease,” leading to diagnostic and treatment guidelines centred around older white men. [19, 20]

The Participation to Prevalence Ratio (PPR) – a metric calculated by dividing the percentage of females in a trial by the percentage of females in the actual disease population – reveals systemic imbalances.[18] A PPR between 0.8 and 1.2 reflects proportional representation, yet many oncology sub-fields fall well below this threshold.[5, 18]

Cancer Site / Field	Female Proportion of Participants	Participation to Prevalence Ratio (PPR)
Bladder Cancer	~24%	0.48 [18]
Head/Neck Cancer	~22%	0.44 [18]
Stomach Cancer	~20%	0.40 [18]
Esophageal Cancer	~20%	0.40 [18]
Surgical Oncology	~37%	0.74 [18]
Cardiology (General)	Varied	-18.68% (Adjusted Relative Difference) [5]

In neurology, immunology, and nephrology, female representation remains consistently lower than the corresponding disability-adjusted life-years (DALYs) for women.[5] The neglect in oncology is particularly damaging for older women, as cancers of the bladder and stomach often present in later life stages where treatment responses may differ significantly from the male cohort.[18] Furthermore, industry-funded trials have shown higher odds of proportional female representation (OR 1.41) compared to government or academic-funded trials, suggesting that private sector research may be more responsive to demographic market realities than public institutions.[18]

Cardiovascular Misdiagnosis and Pharmacological Risks

The failure to include older women in foundational research has resulted in a medical infrastructure that is poorly equipped to recognize the clinical presentation of heart disease in females. [19, 20, 22]

Women experiencing a heart attack are 50% more likely than men to receive an incorrect initial diagnosis. [20, 21]

This is largely due to the “atypical” nature of symptoms in women – which are only considered atypical because they deviate from the male-centric “standard” of radiating chest pain. [20, 23]

The Clinical Manifestation Gap

Physicians, particularly male providers, often under-consider risk factors in women, attributing symptoms to anxiety, stress, or gastrointestinal issues rather than cardiac distress. [20, 23] Nearly half of women do not present with the traditional “typical” symptoms seen in men.[22]

Symptom Category	Male Presentation (Standard)	Female Presentation (Atypical)
Primary Pain	Crushing central chest pain	Back, neck, or jaw pain [20, 22]
Gastrointestinal	Rare	Nausea, indigestion, abdominal pain [20, 22, 24]
Respiratory	Dyspnea (common)	Shortness of breath, unexplained fatigue [20, 22, 24]
Psychological	Fear of death	Malaise, dizziness, intense anxiety [22, 23]

Because diagnostic tools and protocols were developed using male data, women often receive fewer diagnostic tests, such as coronary angiography, ECGs, or cardiac enzyme assessments (troponin levels).[20] Even when women are hospitalized, they are less likely to receive coronary interventions or be referred to cardiac rehabilitation.[7, 20] The result is a documented “gender gap” in mortality, where differences in care have contributed to thousands of avoidable deaths – estimated at over 8,000 in England and Wales over a decade.[21]

Pharmacological Neglect and Adverse Drug Reactions (ADRs)

The consequences of research neglect extend into the pharmacy.[7, 12] Women experience twice as many adverse drug reactions as men for 86 different medications approved by the FDA, including antidepressants, analgesics, and cardiovascular drugs.[7] This disparity arises because most drugs are approved based on trials conducted solely on men or those that include women only in the initial, non-pivotal steps.[7]

 For older women, this (drug-approval trials conducted solely on men) leads to higher levels of over-medication, dosage inaccuracy, and susceptibility to drug-induced liver injury.[7]

Dosing studies rarely account for the metabolic changes that occur post-menopause, leading to a “one-size-fits-all” approach that fundamentally defaults to the male body. [7, 12]

Nutritional Science: From Single Nutrients to Metabolic Patterns

Nutrition for women over 50 has historically focused on a narrow subset of concerns – primarily calcium and vitamin D for bone health – while ignoring the complex metabolic reprogramming that accompanies the transition into menopause.[8, 25, 26] Menopause constitutes a pivotal physiological transition characterized by estrogen depletion, which precipitates accelerated bone resorption, heightened cardiovascular risk, and increased visceral adiposity.[8]

Postmenopausal Osteoporosis and Nutrient Synergy

Research into bone mineral density (BMD) in postmenopausal women has revealed that looking at single nutrients provides an incomplete picture.[26] While calcium and vitamin D are essential, other nutrients like phosphorus, magnesium, and certain fatty acids play critical roles in bone homeostasis.[25, 26] For example, a nutrient pattern high in riboflavin, phosphorus, and calcium is significantly positively correlated with spine BMD (p<0.05,r=0.197), whereas patterns high in vitamin E and omega-6 fatty acids have been shown to be detrimental to bone health in some postmenopausal cohorts.[26]

Nutritional Factor	Effect on Postmenopausal Bone Health	Mechanism
Calcium / vitamin D	Robust Preservation of BMD	Enhances bone structure and mineral absorption [8, 25]
Saturated Fatty Acids	Negative / Promotes Loss	Form complexes with calcium, leading to elimination [25]
Polyunsaturated (n-3)	Positive / Protective	Modulates osteoclasts and regulates calcium metabolism [25, 27]
Riboflavin / Niacin	Positive	Associated with higher spine BMD in midlife women [26]
Dietary Acid Load	Negative	Estrogen deficiency makes women more susceptible to acidosis [26]

The “Western diet,” high in saturated fats and lacking alkali-forming metabolites from fruits and vegetables, is increasingly viewed as a factor for the higher prevalence of osteoporosis in the developed world.[26] In postmenopausal women, the combination of age-related acidity and estrogen deficiency necessitates a shift toward anti-inflammatory dietary patterns, such as the Mediterranean diet, which has demonstrated clinically meaningful reductions in triglycerides and blood pressure.[8, 25]

The Global Micronutrient Gap

A comprehensive global analysis indicates that most of the world population consumes inadequate quantities of micronutrients, with significant sex differences emerging in the 50-plus demographic. [28, 29] Women are more prone to inadequate intakes of iodine, vitamin B12, iron, and selenium. [28, 30] For exercising older women, the “nutrient gap” is even more pronounced. [28, 31]

One study found that for 16 out of 17 micronutrients, females had significantly lower intakes relative to the Estimated Average Requirement (EAR) compared to males (p<0.001).[31] For instance, 59.8% of active females were below the EAR for calcium, compared to only 27.6% of males.[31]

This chronic underconsumption (of micronutrients) in active older women is noteworthy given the importance of these nutrients for maintaining bone health and preventing the onset of sarcopenia – the age-related loss of muscle mass. [8, 31, 32]

Longevity and the Paradox of Female Ageing

The field of biogerontology has long been fascinated by the “longevity gap” – the fact that women consistently outlive men by an average of five to seven years.[1, 3, 12] However, the frameworks shaping the future of ageing research rarely centre on female biology, often defaulting to the male body for testing biomarkers and interventions.[2, 12] This is particularly ironic given that women constitute 90% of super centenarians – those who live to 110 or more.[33]

Biological Mechanisms and Evolutionary Hypotheses

Several theories attempt to explain why females age differently than males. The “heterogametic sex hypothesis” suggests that mammalian females, with two X chromosomes, possess a survival advantage over XY males, who lack a second X chromosome to mask deleterious mutations.[2, 34] Additionally, the “Mother’s Curse” hypothesis posits that because mitochondria are only maternally inherited, they are under selection for compatibility only with the female nuclear genome, potentially leaving males at a disadvantage in mitochondrial function and ageing.[2, 33, 35]

Evolutionary Theory	Predicted Beneficiary	Mechanism
Heterogametic Sex	Homogametic Sex (Females)	“Backup” X-chromosome masks recessive mutations [33, 34]
Mother’s Curse	Females	Maternal inheritance favours female-compatible mtDNA [2, 35]
Grandmother Hypothesis	Post-menopausal Females	Survival favoured to support offspring’s reproductive success [34]
Williams Hypothesis	Sex with lower extrinsic hazard	Evolved slower ageing due to lower environmental risk [1, 36]

Despite these potential biological advantages, women over 50 face a “health-survival paradox” where their higher life expectancy is counterbalanced by a worse quality of life. [1, 3]

Women are more susceptible to frailty and chronic diseases such as Alzheimer’s, which affects women at twice the rate of men.[3, 12, 37] Nearly two-thirds of Alzheimer’s patients are women, not merely because they live longer, but because unique hormonal and mitochondrial changes – such as the decline of E2 during menopause – meaningfully affect ageing at the cellular level.[12]

The Neglect of Post-Reproductive Biology

A critical gap in longevity research is the failure to distinguish between “ageing rate” and “lifespan”.[33, 34] While females live longer, they do not necessarily age more slowly than males in terms of the exponential rate of mortality increase.[1, 33] Much of the research has focused on reproductive success as the primary driver of evolution, leading to a neglect of the post-reproductive phase as a legitimate area of biological inquiry.[10, 38]

This “reproductive-centric” view has historically relegated the study of menopause and post-menopausal health to the periphery of biogerontology, treating it as an “atypical” or “niche” segment of the population rather than the future reality for half the global population. [6, 10]

Artificial Intelligence and the Scaling of Bias

As the healthcare sector increasingly pivots toward AI-driven insights and predictive analytics, the risk of embedding historical gender and age biases into advanced systems has become a central ethical and clinical concern.[12, 39, 40] AI systems are only as effective as the data used to train them, and if the underlying datasets over-represent male, white, and affluent populations, the resulting algorithms will inevitably generate male-default recommendations.[24, 41, 42]

Algorithmic Bias in Healthcare

Assessments of AI models have revealed “fairness gaps” where algorithms perform less accurately for women and people of colour. [9, 39, 43]

 In cardiology, for example, an algorithm trained predominantly on male samples may fail to recognize the “atypical” heart attack symptoms in women, leading to misdiagnosis.[11] Studies have shown that some diagnostic AI models are very good at predicting a patient’s gender and age even when not trained on those tasks, which may lead them to use these traits as “demographic shortcuts” instead of clinical data.[43]

AI Application	Specific Bias / Outcome for Women 50+	Mechanism of Bias
Clinical Diagnosis	Underdiagnosis of heart attacks and stroke [11, 19]	Training data over-represents male symptoms [24]
Medical Imaging	Lower accuracy in diagnosing skin cancer for non-white women	Dataset shifts and unrepresentative cohorts [39, 43]
Digital Patient Twins	Inaccurate disease progression modelling	Failure to incorporate hormonal influence [24, 42]
Mental Health Screening	Under-detection of depression/anxiety in certain groups	Bias in speech pattern and text training [44]

A particularly concerning development is the use of “Digital Patient Twins” (DPTs) – advanced predictive models designed to personalize treatment. [24, 42]

Current DPTs often fail to incorporate gender-sensitive and socio-economic factors, such as hormonal shifts post-menopause or the “digital gender gap” that limits data collection for women in low-income regions. [24, 41, 45]

Without intersectional frameworks, these AI tools risk reinforcing existing inequalities rather than mitigating them. [24, 42]

LLMs and the Perpetuation of Gendered Ageism

The bias against older women is not limited to clinical AI; it is deeply embedded in Large Language Models (LLMs) used in the broader economy.[46]

Research by Stanford researchers found that LLMs like ChatGPT consistently portray hypothetical women as younger and less experienced than men when generating resumes or evaluating job performance.[46]

When ChatGPT was asked to generate over 34,500 unique resumes, it consistently wove younger work histories into female profiles, even when provided with the same initial qualifications as male profiles.[46] When evaluating these resumes, the AI gave older men the highest ratings, putting older women and younger jobseekers at a distinct disadvantage.[46] This suggests that AI tools used in recruitment may actively reinforce “gendered ageism,” which sees women’s value decline as they age while men’s value is preserved or enhanced by their experience.[46, 47]

The “Femtech” Gap and the Economic Imperative

The rise of the “Femtech” industry – digital health products specifically for women – has been touted as a solution to historical neglect. [10, 48, 49] However, an analysis of the Femtech landscape reveals a profound mismatch between the solutions available and the actual needs of women over 50. [10, 49]

The Reproductive Bias in Innovation

Despite a projected market value of $60 billion by 2027, Femtech remains heavily skewed toward fertility, pregnancy, and period tracking. [10, 48, 49]

These areas attract substantial investment and media attention, often generating “hype” that distracts from equally urgent but under-addressed segments like chronic pain, autoimmune disorders, and menopause.[49]

Femtech Focus Area	Funding / Investment Profile	Prevalence / Need in Women 50+
Oncology / Gynaecology	Top Funded Areas [49]	Significant (Cancers of the reproductive system)
Fertility / Pregnancy	Substantial Hype / Media Attention	Low (Irrelevant for post-menopausal cohort)
Menopause	Emerging but Under-funded	High (Universal transition for women 50+)
Cardiovascular / Autoimmune	Low Focus / “Ghost Markets” [49]	Highest Prevalence / Mortality Risk [49]

Critical areas like cardiovascular disease and autoimmune conditions, which disproportionately affect older women, remain “ghost markets” where innovation is sparse.[49] Furthermore, many current Femtech products are not covered by insurance, making them inaccessible to women from lower socioeconomic backgrounds, thus deepening health disparities.[49]

Critics argue that the Femtech industry often exploits anxieties about ageing and attractiveness, marketing useless wellness products through feminist-coded messages of “empowerment”. [48, 50, 51]

The ROI of Women’s Health Research

The failure to invest in women’s health research is increasingly recognized as a missed economic opportunity.[37] The WHAM (Women’s Health Access Matters) report found that increasing funding for women-focused research produces enormous returns for families, businesses, and the broader economy.[37]

• Alzheimer’s Research: Doubling the investment in women’s Alzheimer’s research would pay for itself three times over – a 224% return on investment.[37]
• Heart Disease Research: For every dollar invested in women’s heart disease research, $95 is generated back into the economy.[37]

Longevity Market: While the global longevity market is expected to exceed $500 billion by 2030, women-focused solutions currently capture less than 1% of that investment.[12]

These statistics underscore that closing the research gap for women 50 plus is not just a matter of social justice but a pragmatic economic imperative. [37, 52]

Conclusion: Toward an Intersectional Model of Healthy Ageing

The comprehensive analysis of research in nutrition, health, longevity, and AI demonstrates that women aged 50 and older remain a profoundly neglected demographic. [4, 5, 7, 12]

The “male-as-default” model of the 20th century has evolved into a “digital gender gap” in the 21st, where biased algorithms and unrepresentative clinical data continue to deny older women the precision care they deserve. [9, 24, 39]

The neglect is rooted in a historical view of the female body as a reproductive vessel, leading to a precipitous drop in research interest once the childbearing years have passed.[6, 10] This is evidenced by the declining enrolment rates of women in clinical trials as they age and the persistent misdiagnosis of life-threatening conditions like heart disease.[16, 19, 20] Furthermore, the nutritional needs of post-menopausal women are often reduced to a handful of vitamins, ignoring the systemic metabolic and inflammatory shifts that define the ageing process.[8, 26]

To rectify these disparities, a fundamental shift in the research paradigm is required. This includes:

1. Mandatory Sex and Age Stratification: Research funding should be contingent upon the inclusion of women across the lifespan and the valid analysis of sex-disaggregated data. [14, 15]
2. Addressing Intersectional Invisibility: Longevity and AI research must account for how gender, age, and socioeconomic status intersect to create unique health vulnerabilities. [4, 24, 53]
3. Broadening the Definition of Women’s Health: Innovation must move beyond reproductive health to encompass the chronic and systemic conditions that define the lives of women over 50, including cardiovascular health, autoimmune diseases, and cognitive decline. [10, 12, 49]

The longevity paradox – the fact that women live longer but sicker – is not an immutable biological law; it is a signal of a scientific infrastructure that has failed to prioritise the quality of female life in later stages. [3, 12] By treating the biology of women aged 50 and older not as an “exception” but as a foundation for research, the global scientific community can finally deliver on the promise of healthy, equitable ageing for all. [3, 12, 54]

Here’s a polished version with a touch of British humour, slightly expanded but still natural and restrained:

---

As you reach the end of this article, you may have noticed that some parts lean towards the theoretical side. That is quite intentional. As mentioned in the introduction, I encourage you to come back to this piece—or follow me on LinkedIn—where I will be sharing shorter, more practical reflections, complete with real‑life suggestions and fewer abstract gymnastics.

In the meantime, don’t be shy, don’t fade quietly into the background like an awkward guest at a networking event. Join the conversation, challenge the ideas, or simply nod along politely. One way or another, I’m not going anywhere just yet.
#IamNotDoneYet

Sources

1. Sex Differences in Longevity and Ageing | Request PDF – ResearchGate, https://www.researchgate.net/publication/279426735_Sex_Differences_in_Longevity_and_Ageing
2. Sex differences in biological ageing with a focus on human studies – eLife, https://elifesciences.org/articles/63425
3. Gender, ageing and longevity in humans: an update of an intriguing/neglected scenario paving the way to a gender-specific medicine – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC4994139/
4. Disparities in women’s health and clinical considerations from a translational science perspective: A narrative review and framework for future directions – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12657800/
5. Analysis of Female Enrollment and Participant Sex by Burden of Disease in US Clinical Trials Between 2000 and 2020 – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8214160/
6. Overview of the National Institutes of Health Investment in Women’s …, https://www.ncbi.nlm.nih.gov/books/NBK612400/
7. Uncovering the gender health data gap – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10494683/
8. Dietary interventions and nutritional strategies for menopausal health: a mini review, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1702105/full
9. The Role of Gender in AI Medical Tools: Are algorithms reproducing human bias in healthcare delivery?, https://amwa-doc.org/the-role-of-gender-in-ai-medical-tools-are-algorithms-reproducing-human-bias-in-healthcare-delivery/
10. Toward a Life Course Model of Innovation: FemTech and the New Health Economy – HMPI, https://hmpi.org/2025/10/07/toward-a-life-course-model-of-innovation-femtech-and-the-new-health-economy/
11. Addressing bias in big data and AI for health care: A call for open science – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8515002/
12. The Longevity Gap: How Ageing Research Leaves … – Observer, https://observer.com/2026/01/women-health-longevity-systemic-bias/
13. Why we know so little about women’s health – AAMC, https://www.aamc.org/news/why-we-know-so-little-about-women-s-health
14. History of Women’s Participation in Clinical Research, https://orwh.od.nih.gov/toolkit/recruitment/history
15. NIH Inclusion Policies – Office of Research on Women’s Health, https://orwh.od.nih.gov/nih-inclusion-policies
16. Underrepresentation of women in randomized controlled trials: a …, https://pubmed.ncbi.nlm.nih.gov/36539814/
17. Key Trends in Demographic Diversity in Clinical Trials – NCBI – NIH, https://www.ncbi.nlm.nih.gov/books/NBK584392/
18. Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020 – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10243778/
19. Research: Developing Solutions for Misdiagnosis of Heart Disease in Women., https://www.medstarhealth.org/blog/cardiovascular-diagnosis-research
20. Gender Bias in Diagnosis, Prevention, and Treatment of … – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC10945154/
21. Gender Gap Report – Heart Research UK, https://heartresearch.org.uk/support-us/get-involved/her-disease/gender-gap-report/
22. The Mounting Crisis in Women’s Heart Health | Columbia Surgery, https://columbiasurgery.org/news/mounting-crisis-women-s-heart-health
23. “Ms. Diagnosed”: Why Women’s Heart Disease Symptoms Are Often Overlooked, https://www.womenheart.org/womens-heart-disease-symptoms-overlooked/
24. Beyond the gender data gap: co-creating equitable digital patient twins – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12075337/
25. Nutrition-Based Support for Osteoporosis in Postmenopausal Women: A Review of Recent Evidence – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11034565/
26. The Relationship between Nutrient Patterns and Bone Mineral Density in Postmenopausal Women – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6628050/
27. Nutrition and Women’s Bone Health – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC8877096/
28. Sex differences in nutrient gaps among active adults – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12800541/
29. Billions worldwide consume inadequate levels of micronutrients critical to human health, https://hsph.harvard.edu/news/billions-worldwide-consume-inadequate-levels-of-micronutrients-critical-to-human-health/
30. Sex differences in nutrient gaps among active adults – ResearchGate, https://www.researchgate.net/publication/399383439_Sex_differences_in_nutrient_gaps_among_active_adults
31. Sex Differences in Nutrient Gaps in Active Adults, https://digitalcommons.wku.edu/ijesab/vol2/iss17/32/
32. Menopausal Status-Dependent Alterations in Bone Mineral Density in Women Transitioning from Menopause to Postmenopause: An Observational Multicenter Study – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12220895/
33. Sex differences in adult lifespan and ageing rates of mortality across wild mammals – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC7165438/
34. Why women live longer than men, explained by evolution | ScienceDaily, https://www.sciencedaily.com/releases/2025/10/251027225628.htm
35. Sex- and age-differences in cellular hallmarks of ageing in a species with female – bioRxiv, https://www.biorxiv.org/content/10.64898/2025.12.10.693506v1.full.pdf
36. Sex Differences in Lifespan – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC4932837/
37. The gender gap in health research funding is hurting all of us – Northwell Health, https://www.northwell.edu/katz-institute-for-womens-health/articles/gender-gap-in-health-research
38. Why Men Don’t Live as Long as Women – Nautilus, https://nautil.us/why-men-dont-live-as-long-as-women-236547
39. Algorithm fairness in artificial intelligence for medicine and healthcare – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC10632090/
40. Big data and AI for gender equality in health: bias is a big challenge – Frontiers, https://www.frontiersin.org/journals/big-data/articles/10.3389/fdata.2024.1436019/full
41. Algorithmic bias in public health AI: a silent threat to equity in low-resource settings – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12325396/
42. Beyond the gender data gap: co-creating equitable digital patient twins – Frontiers, https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2025.1584415/full
43. Study reveals why AI models that analyze medical images can be biased | MIT News, https://news.mit.edu/2024/study-reveals-why-ai-analyzed-medical-images-can-be-biased-0628
44. AI in Mental Health Diagnostics – The University of Alabama at Birmingham, https://sites.uab.edu/humanrights/2025/11/21/ai-in-mental-health-diagnostics/
45. The Digital Gender Gap in HealthCare, https://genderhealthdata.org/wp-content/uploads/2024/01/The-Digital-Gender-Gap-in-HealthCare.pdf
46. Researchers uncover AI bias against older working women | Stanford Report, https://news.stanford.edu/stories/2025/10/ai-llms-age-bias-older-working-women-research
47. Women’s Perceptions and Use of “Anti-Ageing” Products – ResearchGate, https://www.researchgate.net/publication/225143749_Women’s_Perceptions_and_Use_of_Anti-Ageing_Products
48. Full article: The new patriarchal digitality? Understanding gendered power dynamics through a systematic review of femtech apps in China – Taylor & Francis, https://www.tandfonline.com/doi/full/10.1080/09718524.2025.2503561
49. Femtech’s Rise and Roadblocks: Digital Health Funding, Growth and Gaps, https://www.galengrowth.com/femtechs-rise-and-roadblocks-digital-health-funding-growth-and-gaps/
50. Companies marketing useless health products to women using feminist wellbeing messages – The Guardian, https://www.theguardian.com/australia-news/2024/feb/15/companies-marketing-useless-health-products-to-women-using-feminist-wellbeing-messages
51. Manageing and Monitoring the Menopausal Body | The University of Chicago Legal Forum, https://legal-forum.uchicago.edu/print-archive/manageing-and-monitoring-menopausal-body
52. Over-50s feel neglected by brands, finds study | News | Research Live, https://www.research-live.com/article/news/over50s-feel-neglected-by-brands-finds-study/id/5141843
53. Frameworks encompassing intersectional perspective of artificial …, https://pmc.ncbi.nlm.nih.gov/articles/PMC12803852/
54. INVESTING IN WOMEN’S HEALTH RESEARCH AND INNOVATION: A PRESCRIPTION TO HEAL OUR FRACTURED SOCIAL CONTRACT – IRIS, https://iris.who.int/bitstreams/ed301707-9fcc-45e5-b64a-2dc196296b0a/download